Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR731 First-in-Human Phase I Study in Metastatic Castration-Resistant Prostate Cancer
jRCT2031260305Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of INR731 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and 3 more. Started Jul 2026; status: recruiting.
02
Drugs
INR731
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031260305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260305.